Direct-acting antivirals: the endgame for hepatitis C?
Roberta D’Ambrosio(University of Southern California), Alessio Aghemo, Massimo Colombo(University of Milan), Elisabetta Degasperi(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico)
Cited by 97
Related Papers
Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission
|The Lancet. Gastroenterology & hepatology|2019|539
A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis
|Hepatology|2012|404
High rates of 30-day mortality in patients with cirrhosis and COVID-19
|Journal of Hepatology|2020|392
Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores
|Journal of Hepatology|2020|361
Impact of COVID-19 on global HCV elimination efforts
|Journal of Hepatology|2020|279